Buscar resultados de ensayos clínicos
Desmoid Tumor - 26 Studies Found
Estado | Estudiar |
Withdrawn |
Nombre del estudio: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors Condición:
Fecha: 2009-09-15 Intervenciones: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w |
Completed |
Nombre del estudio: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis Condición: Desmoid Tumor Fecha: 2006-02-06 Intervenciones: Drug: imatinib mesylate |
Active, not recruiting |
Nombre del estudio: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Condición:
Fecha: 2009-06-25 Intervenciones: Drug: Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months |
Recruiting |
Nombre del estudio: National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) Condición: Aggressive Fibromatosis Fecha: 2016-07-15 Intervenciones:
|
Recruiting |
Nombre del estudio: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Condición: Desmoid Type-fibromatosis Fecha: 2015-01-28 Intervenciones: Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression |
Recruiting |
Nombre del estudio: Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients Condición: Desmoid-type Fibromatosis Fecha: 2015-01-28 Intervenciones: Other: Observational approach Patients will be placed under wait and see approach without any specific t |
Active, not recruiting |
Nombre del estudio: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Condición: Desmoid-Type Fibromatosis Fecha: 2014-02-17 Intervenciones:
|
Recruiting |
Nombre del estudio: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors Condición:
|
Completed |
Nombre del estudio: A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome Condición:
Fecha: 2016-11-02 Intervenciones: Drug: PF-03084014 Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084 |